Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Liu

Showing results (331-340 of 361) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastomaErin F Simonds, Edbert D Lu, Oscar Badillo, et al.
Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell CarcinomaElizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
The New England Journal of Medicine|May 25, 2022
Demethylation and Up-Regulation of an Oncogene after Hypomethylating TherapyYao-Chung Liu, Junsu Kwon, Emiliano Fabiani, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Stem Cell Reports|May 10, 2023
Single-cell transcriptome analysis of xenotransplanted human retinal organoids defines two migratory cell populations of nonretinal originYing V Liu, Clayton P Santiago, Akin Sogunro, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Pageof 37

Showing results (331-340 of 361) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastomaErin F Simonds, Edbert D Lu, Oscar Badillo, et al.
Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell CarcinomaElizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
The New England Journal of Medicine|May 25, 2022
Demethylation and Up-Regulation of an Oncogene after Hypomethylating TherapyYao-Chung Liu, Junsu Kwon, Emiliano Fabiani, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Stem Cell Reports|May 10, 2023
Single-cell transcriptome analysis of xenotransplanted human retinal organoids defines two migratory cell populations of nonretinal originYing V Liu, Clayton P Santiago, Akin Sogunro, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Pageof 37